{
    "key_points": [
        "The FDA authorized several tests for over-the-counter (OTC) use without a prescription for serial screening of asymptomatic individuals.",
        "One serial screening test was authorized for point-of-care (POC) setting without a prescription and another for POC use with a prescription.",
        "The newly authorized tests are aimed at assisting schools, workplaces, and communities in setting up COVID-19 screening programs.",
        "FDA's Jeff Shuren emphasized the importance of screening testing and assured the public that these tests meet the FDA's scientific standards for emergency use authorization.",
        "The FDA has taken various measures throughout the pandemic to facilitate the development and authorization of COVID-19 tests.",
        "Three tests were specifically mentioned for their authorization for serial screening claims: Quidel QuickVue, Abbott BinaxNOW (in multiple configurations), and BD Veritor System.",
        "The authorized tests had previously been approved for symptomatic testing but have now been extended for asymptomatic use in serial testing.",
        "These authorizations are part of the FDA's efforts to increase consumer access to testing and support the establishment of screening programs.",
        "The FDA's actions are part of its broader mandate to ensure public health by regulating drugs, medical devices, food supply, and other areas.",
        "The aim is to offer several options for accurate and reliable screening tests to control the spread of COVID-19."
    ],
    "spokespersons": [
        "Jeff Shuren, M.D., J.D. (director, FDA's Center for Devices and Radiological Health)"
    ],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}